...
【24h】

Endovascular therapy of inflammatory aortic aneurysms: a meta-analysis.

机译:炎性主动脉瘤的血管内治疗:一项荟萃分析。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To report a meta-analysis of results from endovascular aneurysm repair (EVAR) of inflammatory aortic aneurysms (IAA). METHODS: A comprehensive literature review was performed to identify all studies reporting the results of EVAR in patients with IAA. To be included in the analysis, an article had to provide a minimum follow-up of 6 months, information about primary technical success, details of immediate and long-term complications, and evaluation of at least one of the basic outcome criteria: changes in aneurysm sac diameter, periaortic fibrosis (PAF), and/ or renal impairment. All studies were reviewed by 2 independent observers for the inclusion criteria. Data were retrieved on the technical and clinical success, outcome criteria, mortality in follow-up, and reinterventions from 14 articles selected from among 701 initially identified. RESULTS: The 14 articles encompassed 46 patients (45 men [97.8%]; mean age 65 years, range 59-75) with a mean follow-up of 18 months after endovascular repair of IAAs located in the abdominal aorta. The primary technical success rate was 95.6% (44/46) and the 30-day clinical success rate was 93.4% (43/46). The median aneurysm sac diameter regression was 11 mm. Of 43 patients with PAF prior to the intervention, 22 (51.2%) patients showed complete regression, 18 (41.8%) remained unchanged, and 3 (7.0%) showed progression after EVAR. Renal impairment disappeared in 11 (45.8%) of 24 patients. Reinterventions were reported in 8 patients. The procedure-related and follow-up mortality rates were 0% and 13.0%, respectively. CONCLUSIONS: EVAR of IAA is feasible, excludes the aneurysm effectively, and reduces PAF and renal impairment in most patients with very low periprocedural and midterm mortality and an acceptable reintervention rate.
机译:目的:报告对炎性主动脉瘤(IAA)的血管内动脉瘤修复(EVAR)结果的荟萃分析。方法:进行了全面的文献综述,以鉴定所有报告IAA患者EVAR结果的研究。要包括在分析中,一篇文章必须提供至少6个月的随访,有关主要技术成功的信息,即时和长期并发症的详细信息以及至少一项基本结果标准的评估:动脉瘤囊直径,腹主动脉纤维化(PAF)和/或肾功能不全。所有研究均由2名独立观察员审查,以纳入标准。从最初确定的701篇中选择了14篇文章,检索了有关技术和临床成功率,结果标准,随访死亡率和再次干预的数据。结果:这14篇文章涵盖46例患者(45名男性[97.8%];平均年龄65岁,范围59-75),对位于腹主动脉的IAA进行腔内修复后平均随访18个月。主要技术成功率为95.6%(44/46),30天临床成功率为93.4%(43/46)。中位动脉瘤囊直径回归值为11 mm。在介入治疗前的43位PAF患者中,有22位(51.2%)患者表现出完全消退,18位(41.8%)保持不变,而3位(7.0%)在EVAR后进展。 24例患者中有11例(45.8%)肾功能损害消失。据报道有8例患者再次介入治疗。与手术相关的死亡率和随访死亡率分别为0%和13.0%。结论:IAA的EVAR是可行的,可以有效排除动脉瘤,并能降低大多数围手术期和中期死亡率很低且再介入率可接受的患者的PAF和肾功能损害。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号